Prognostic value of SUVmax on 18F-fluorodeoxyglucose PET/CT scan in patients with malignant pleural mesothelioma

被引:18
作者
Lim, Jun Hyeok [1 ,2 ]
Choi, Joon Young [3 ]
Im, Yunjoo [1 ]
Yoo, Hongseok [1 ]
Jhun, Byung Woo [1 ]
Jeong, Byeong-Ho [1 ]
Park, Hye Yun [1 ]
Lee, Kyungjong [1 ]
Kim, Hojoong [1 ]
Kwon, O. Jung [1 ]
Han, Joungho [4 ]
Ahn, Myung-Ju [5 ]
Kim, Jhingook [6 ]
Um, Sang-Won [1 ]
机构
[1] Sungkyunkwan Univ, Samsung Med Ctr, Dept Med, Div Pulm & Crit Care Med,Sch Med, Seoul, South Korea
[2] Inha Univ, Inha Univ Hosp, Dept Internal Med, Div Pulmonol,Sch Med, Incheon, South Korea
[3] Sungkyunkwan Univ, Samsung Med Ctr, Dept Nucl Med, Sch Med, Seoul, South Korea
[4] Sungkyunkwan Univ, Samsung Med Ctr, Dept Pathol, Sch Med, Seoul, South Korea
[5] Sungkyunkwan Univ, Samsung Med Ctr, Dept Med, Div Hematol Oncol,Sch Med, Seoul, South Korea
[6] Sungkyunkwan Univ, Samsung Med Ctr, Dept Thorac & Cardiovasc Surg, Sch Med, Seoul, South Korea
来源
PLOS ONE | 2020年 / 15卷 / 02期
关键词
POSITRON-EMISSION-TOMOGRAPHY; EXTRAPLEURAL PNEUMONECTOMY; SURVIVAL; CISPLATIN; CANCER;
D O I
10.1371/journal.pone.0229299
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Introduction The maximum standardized uptake value (SUVmax) in F-18-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) may be of prognostic significance for patients with malignant pleural mesothelioma (MPM). This retrospective study aimed to investigate the prognostic value of the SUVmax in patients with MPM. Materials and methods Medical records were retrospectively reviewed for the patients who were diagnosed with histopathologically proven MPM between 2009 and 2018 at Samsung Medical Center. For each patient, SUVmax was calculated for the primary lesion on PET/CT. To determine optimal cutoff values for predicting mortality, receiver operating characteristic curves were used. Results Among the 54 study patients, 34 (63.0%) had epithelioid subtype, 13 (24.1%) had sarcomatoid or biphasic subtype, and 7 (13.0%) had mesothelioma, not otherwise specified (NOS). The median overall survival (OS) was 8.7 months, and the median SUVmax was 9.9. The median values of SUVmax were 5.5 in patients with epithelioid subtype, 11.7 in those with sarcomatoid/biphasic subtype, and 13.3 in those with NOS subtype (P = 0.003). The optimal cutoff values of SUVmax to predict mortality were 10.1 in all patients, and 8.5 in patients with epithelioid subtype. In multivariate analysis, SUVmax was significantly associated with overall survival in all patients (P = 0.003) and in patients with epithelioid subtype (P = 0.012), but not in those with non-epithelioid subtype. Conclusions SUVmax in PET/CT is an independent prognostic factor in patients with MPM, especially those with epithelioid subtype. The histologic subtype of MPM should be considered when evaluating the prognostic significance of SUVmax.
引用
收藏
页数:11
相关论文
共 25 条
[1]   Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial [J].
Alley, Evan W. ;
Lopez, Juanita ;
Santoro, Armando ;
Morosky, Anne ;
Saraf, Sanatan ;
Piperdi, Bilal ;
van Brummelen, Emilie .
LANCET ONCOLOGY, 2017, 18 (05) :623-630
[2]   Contemporary Analysis of Prognostic Factors in Patients with Unresectable Malignant Pleural Mesothelioma [J].
Bille, Andrea ;
Krug, Lee M. ;
Woo, Kaitlin M. ;
Rusch, Valerie W. ;
Zauderer, Marjorie G. .
JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (02) :249-255
[3]   Prognostic factors in elderly patients with malignant pleural mesothelioma: results of a multicenter survey [J].
Ceresoli, G. L. ;
Grosso, F. ;
Zucali, P. A. ;
Mencoboni, M. ;
Pasello, G. ;
Ripa, C. ;
Degiovanni, D. ;
Simonelli, M. ;
Bruzzone, A. ;
Dipietrantonj, C. ;
Piccolini, E. ;
Beretta, G. D. ;
Favaretto, A. G. ;
Giordano, L. ;
Santoro, A. ;
Botta, M. .
BRITISH JOURNAL OF CANCER, 2014, 111 (02) :220-226
[4]   Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18F]fluorodeoxyglucose [J].
Ceresoli, Giovanni L. ;
Chiti, Arturo ;
Zucali, Paolo A. ;
Rodari, Marcello ;
Lutman, Romano F. ;
Salamina, Silvia ;
Incarbone, Matteo ;
Alloisio, Marco ;
Santoro, Armando .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (28) :4587-4593
[5]   Prognostic factors in patients with pleural mesothelioma: The European Organization for Research and Treatment of Cancer experience [J].
Curran, D ;
Sahmoud, T ;
Therasse, P ;
van Meerbeeck, J ;
Postmus, PE ;
Giaccone, G .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (01) :145-152
[6]   Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial [J].
Disselhorst, Maria J. ;
Quispel-Janssen, Josine ;
Lalezari, Ferry ;
Monkhorst, Kim ;
de Vries, Jeltje F. ;
van der Noort, Vincent ;
Harms, Emmy ;
Burgers, Sjaak ;
Baas, Paul .
LANCET RESPIRATORY MEDICINE, 2019, 7 (03) :260-270
[7]   Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center [J].
Flores, Raja M. ;
Zakowski, Maureen ;
Venkatraman, Ennapadam ;
Krug, Lee ;
Rosenzweig, Kenneth ;
Dyeoeo, Joseph ;
Lee, Catherine ;
Yeoh, Cindy ;
Bains, Manjit ;
Rusch, Valerie .
JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (10) :957-965
[8]   Positron emission tomography predicts survival in malignant pleural mesothelioma [J].
Flores, Raja M. ;
Akhurst, Timothy ;
Gonen, Mithat ;
Zakowski, Maureen ;
Dycoco, Joseph ;
Larson, Steven M. ;
Rusch, Valerie W. .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2006, 132 (04) :763-768
[9]   Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B [J].
Herndon, JE ;
Green, MR ;
Chahinian, AP ;
Corson, JM ;
Suzuki, Y ;
Vogelzang, NJ .
CHEST, 1998, 113 (03) :723-731
[10]   High SUVmax on FDG-PET Indicates Pleomorphic Subtype in Epithelioid Malignant Pleural Mesothelioma Supportive Evidence to Reclassify Pleomorphic as Nonepithelioid Histology [J].
Kadota, Kyuichi ;
Kachala, Stefan S. ;
Nitadori, Jun-ichi ;
Suzuki, Kei ;
Dunphy, Mark P. S. ;
Sima, Camelia S. ;
Travis, William D. ;
Rusch, Valerie W. ;
Adusumilli, Prasad S. .
JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (07) :1192-1197